BioCentury
ARTICLE | Clinical News

ALN-PCSsc: Updated Phase I data

November 16, 2015 8:00 AM UTC

The partners reported updated data from a single-blind, placebo-controlled, U.K. Phase I trial in 69 healthy subjects on or off statins with elevated baseline LDL-C levels of >100 mg/dL evaluating single and multiple doses of subcutaneous ALN-PCSsc. Updated data showed that the mean maximum percent PCSK9 knockdown relative to baseline for single doses of ALN-PCSsc was up to 82.3% and the mean maximum percent reduction in LDL-C relative to baseline was up to 59.3%. At day 180, ALN-PCSsc led to up to a 53% reduction in LDL-C with a least squares mean reduction of 47% at the 300 mg dose. Additionally, ALN-PCSsc led to maximum reductions of 77% in lipoprotein(a) (LPA), 48% in total cholesterol, 72% in apolipoprotein B (APOB) and 68% in non-HDL-C. There were no significant changes in HDL-C. ...